Journal of Asthma and Allergy · 2021 · 46 citations · 36 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyImmunotherapyPulmonary Function TestingAsthma ManagementAsthma PharmacotherapyDrug AllergyBiologic Therapy For AsthmaBiologic Therapy ManagementEosinophil CountPulmonary Function ChangesSevere Asthma ManagementSevere Asthma TreatmentTreatment Effectiveness AnalysisTreatment Effectiveness Measurement
BACKGROUND: In Japan, biologic therapy was initiated for patients with severe asthma in 2009. In recent years, four biologics with different mechanisms of action have become available in the clinical setting. However, the efficacy of switching between biologics remains uncertain. METHODS: To elucidate the efficacy of switching between biologics, 97 patients were enrolled who had received any biologic therapy for severe asthma at Jikei University Hospital, Tokyo, Japan, from July 2009 to December 2020. We retrospectively examined the patient characteristics, biomarkers, pulmonary function test results, selected biologics, and efficacy. RESULTS: Thirty-one males and 66 females received any biologics. The mean age was 53.3 years at the initiation of biologic therapy. Initially, 33, 41, 15 and eight patients received omalizumab, mepolizumab, benralizumab, and dupilumab, respectively. Among three representative indicators for biologics administration, the peripheral blood eosinophil count, serum IgE levels and fractional exhaled nitric oxide, 64% of the patients had two indicators, and 28% had three indicators. Thirty-four patients (35%) switched from the initial biologic to another, and the reasons for switching included persistent asthmatic symptoms (n=22), schedule of hospital visits (n=5), and other reasons. Thus, the treatment was effective in 11 patients after switching. In addition, two patients received combination therapy with different biologics. Eighteen patients (19%) interrupted treatment for various reasons. Regardless of whether the biologic was the initial therapy, the overall efficacy of the four biologics was 60% based on the global evaluation of treatment effectiveness. CONCLUSION: Switching between biologics can be a promising option for severe asthma patients in whom treatment with an initial biologic is ineffective.
36
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
Romain Pauwels · Arerugī/Arerugi · 1996 · 10.1K citations
Pharmacy, Chronic Disease Prevention, Preventive Medicine +10
American Journal of Respiratory and Critical Care Medicine · 2005 · 3.2K citations
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Héctor Ortega, Mark C. Liu, Ian Pavord et al. · New England Journal of Medicine · 2014 · 2.3K citations · Full text
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Mario Castro, Jonathan Corren, Ian Pavord et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text
Pharmacy, Immunology, Pharmacology +13